Hiroyoshi Nishikawa

List of Publications by Year
in descending order

136	17,314	44042 48	16164 124
papers	citations	h-index	g-index

143	143	143	23755
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. Gastroenterology, 2022, 162, 799-812.	0.6	28
2	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
3	Lactic acid promotes PD-1 expression in regulatory TÂcells in highly glycolytic tumor microenvironments. Cancer Cell, 2022, 40, 201-218.e9.	7.7	266
4	Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2022, 52, 383-387.	0.6	5
5	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. Clinical Cancer Research, 2022, 28, 1136-1146.	3.2	62
6	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted TÂcell clonotypes. Cell Reports, 2022, 38, 110331.	2.9	45
7	Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. Life Science Alliance, 2022, 5, e202101230.	1.3	16
8	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer, 2022, 25, 619-628.	2.7	18
9	The ratio of CD8â€‰+â€‰lymphocytes to tumor-infiltrating suppressive FOXP3â€‰+â€‰effector regulatory T cells is associated with treatment response in invasive breast cancer. Discover Oncology, 2022, 13, 27.	0.8	10
10	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. Haematologica, 2022, 107, 2418-2431.	1.7	14
11	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. Clinical Cancer Research, 2022, 28, 3480-3488.	3.2	8
12	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753.	0.7	2
13	Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization. STAR Protocols, 2022, 3, 101557.	0.5	3
14	Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. International Immunology, 2021, 33, 39-48.	1.8	4
15	A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients. International Journal of Hematology, 2021, 113, 473-479.	0.7	0
16	<scp>HSP90</scp> inhibition overcomes <scp>EGFR</scp> amplificationâ€induced resistance to thirdâ€generation <scp>EGFRâ€TKIs</scp>. Thoracic Cancer, 2021, 12, 631-642.	0.8	14
17	Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. Scientific Reports, 2021, 11, 341.	1.6	17
18	Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. New England Journal of Medicine, 2021, 384, 42-50.	13.9	40

#	Article	IF	Citations
19	Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance. International Journal of Hematology, 2021, 113, 772-774.	0.7	1
20	Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion. Experimental and Molecular Medicine, 2021, 53, 202-209.	3.2	51
21	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. JCI Insight, 2021, 6, .	2.3	17
22	CD4 ⁺ T cells are essential for the development of destructive thyroiditis induced by antiâ€“PD-1 antibody in thyroglobulin-immunized mice. Science Translational Medicine, 2021, 13, .	5.8	47
23	Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. International Immunology, 2021, 33, 435-446.	1.8	14
24	Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. , 2021, 9, e002591.		105
25	Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies. International Immunology, 2021, 33, 551-562.	1.8	20
26	Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. , 2021, 9, e002279.		19
27	A mixture-of-experts deep generative model for integrated analysis of single-cell multiomics data. Cell Reports Methods, 2021, 1, 100071.	1.4	47
28	TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). Clinical Cancer Research, 2021, 27, 6709-6715.	3.2	20
29	Antitumour immunity regulated by aberrant ERBB family signalling. Nature Reviews Cancer, 2021, 21, 181-197.	12.8	141
30	Vescimonas gen. nov., Vescimonas coprocola sp. nov., Vescimonas fastidiosa sp. nov., Pusillimonas gen. nov. and Pusillimonas faecalis sp. nov. isolated from human faeces. International Journal of Systematic and Evolutionary Microbiology, 2021, 71, .	0.8	21
31	CYBERTRACK2.0: zero-inflated model-based cell clustering and population tracking method for longitudinal mass cytometry data. Bioinformatics, 2021, 37, 1632-1634.	1.8	1
32	Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. Cancers, 2021, 13, 5904.	1.7	3
33	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Science Immunology, 2021, 6, eabc6424.	5.6	64
34	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications, 2021, 12, 7280.	5.8	11
35	Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.. Nagoya Journal of Medical Science, 2021, 83, 827-840.	0.6	6
36	The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. International Immunology, 2020, 32, 273-281.	1.8	10

#	Article	IF	Citations
37	Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. Journal of Experimental Medicine, 2020, 217, .	4.2	58
38	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). Clinical Cancer Research, 2020, 26, 5887-5894.	3.2	44
39	The critical role of CD4+ T cells in PD-1 blockade against MHC-IIâ€“expressing tumors such as classic Hodgkin lymphoma. Blood Advances, 2020, 4, 4069-4082.	2.5	76
40	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nature Immunology, 2020, 21, 1346-1358.	7.0	431
41	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. Frontiers in Immunology, 2020, 11, 578848.	2.2	11
42	Endoscopic Activity and Serum TNF-Î± Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohnâ€™s Disease Patients. Inflammatory Bowel Diseases, 2020, 26, 1669-1681.	0.9	8
43	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. Gastric Cancer, 2020, 23, 893-903.	2.7	20
44	An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Immunity, 2020, 53, 187-203.e8.	6.6	119
45	Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated nonâ€“small cell lung cancer. Science Immunology, 2020, 5, .	5.6	160
46	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of Clinical Oncology, 2020, 38, 2053-2061.	0.8	469
47	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epsteinâ€“Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer, 2019, 22, 69-76.	2.7	45
48	A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. Clinical Cancer Research, 2019, 25, 6614-6622.	3.2	106
49	Regulatory T cells in cancer immunosuppression â€” implications for anticancer therapy. Nature Reviews Clinical Oncology, 2019, 16, 356-371.	12.5	872
50	Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Science, 2019, 110, 2080-2089.	1.7	614
51	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 165-174.	1.8	123
52	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clinical Cancer Research, 2019, 25, 4808-4819.	3.2	66
53	PD-1⁺regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9999-10008.	3.3	655
54	Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Antiâ€“PD-1 Therapy. Journal of Investigative Dermatology, 2019, 139, 1490-1496.	0.3	15

#	Article	IF	Citations
55	Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. Journal of Experimental Medicine, 2019, 216, 2701-2713.	4.2	82
56	Model-based cell clustering and population tracking for time-series flow cytometry data. BMC Bioinformatics, 2019, 20, 633.	1.2	10
57	Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered antiâ€“CTLA-4 antibody. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 609-618.	3.3	141
58	Internal Medicine, 2019, 108, 430-437.	0.0	0
59	Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients. Blood, 2019, 134, 192-192.	0.6	0
60	Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy. Blood, 2019, 134, 1792-1792.	0.6	0
61	ï¼œEditors' Choiceï¼ž Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. Nagoya Journal of Medical Science, 2019, 81, 1-18.	0.6	18
62	Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis. Cancer Immunology Research, 2018, 6, 378-388.	1.6	35
63	Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. Journal of Cancer Research and Clinical Oncology, 2018, 144, 835-844.	1.2	7
64	Regulatory T cells: a potential target in cancer immunotherapy. Annals of the New York Academy of Sciences, 2018, 1417, 104-115.	1.8	184
65	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. International Immunology, 2018, 30, 13-22.	1.8	74
66	Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumonia. Lung Cancer, 2018, 126, 162-169.	0.9	2
67	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
68	Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica, 2018, 103, 1835-1842.	1.7	59
69	Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients.. Journal of Clinical Oncology, 2018, 36, 4106-4106.	0.8	14
70	Classification of idiopathic interstitial pneumonias using antiâ€“myxovirus resistance-protein 1 autoantibody. Scientific Reports, 2017, 7, 43201.	1.6	14
71	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. Current Topics in Microbiology and Immunology, 2017, 410, 3-27.	0.7	48
72	Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 1517-1523.	0.8	48

#	Article	IF	Citations
73	Regulatory T cells, as a target in anticancer immunotherapy. Immunotherapy, 2017, 9, 623-627.	1.0	9
74	ICOS⁺Foxp3⁺TILs in gastric cancer are prognostic markers and effector regulatory T cells associated withHelicobacter pylori. International Journal of Cancer, 2017, 140, 686-695.	2.3	100
75	Possible Biomarker for immune checkpoint inhibitor. Annals of Oncology, 2017, 28, ix20.	0.6	0
76	Suppression from beyond the grave. Nature Immunology, 2017, 18, 1285-1286.	7.0	10
77	Regulatory-T cells (Tregs) in tumor infiltrating lymphocytes (TILs) from patients with advanced gastric cancer (AGC) after chemotherapy containing ramucirumab.. Journal of Clinical Oncology, 2017, 35, e15570-e15570.	0.8	0
78	Regulatory T cells as a target of cancer immunotherapy. Annals of Oncology, 2016, 27, vii3.	0.6	0
79	Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. PLoS ONE, 2016, 11, e0160576.	1.1	15
80	Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood, 2016, 128, 2083-2088.	0.6	279
81	Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia. Cancer Immunology Research, 2016, 4, 644-649.	1.6	23
82	Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nature Medicine, 2016, 22, 679-684.	15.2	641
83	Roles of regulatory T cells in cancer immunity. International Immunology, 2016, 28, 401-409.	1.8	412
84	Analysis of CCR4-expressing T cells in patients with rhododenol-induced leukoderma. Journal of Dermatological Science, 2016, 84, e13.	1.0	0
85	Report on the use of nonâ€clinical studies in the regulatory evaluation of oncology drugs. Cancer Science, 2016, 107, 189-202.	1.7	6
86	Identification of Novel and Noninvasive Biomarkers of Acute Cellular Rejection After Liver Transplantation by Protein Microarray. Transplantation Direct, 2016, 2, e118.	0.8	9
87	Hypomethylation of the Treg-Specific Demethylated Region in FOXP3 Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia. Cancer Immunology Research, 2016, 4, 136-145.	1.6	20
88	Kinetics of Regulatory T Cells Predict the Recurrence of CML after Stopping Imatinib in Japanese CML Patiens. Blood, 2016, 128, 4240-4240.	0.6	0
89	Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes. Blood, 2016, 128, 4577-4577.	0.6	0
90	Overview: New Modality for Cancer Treatment. Oncology, 2015, 89, 33-35.	0.9	5

#	Article	IF	Citations
91	Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 ^{high} regulatory T cells in humans. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7225-7230.	3.3	164
92	Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clinical Cancer Research, 2015, 21, 4327-4336.	3.2	187
93	Regulatory T cells in cancer; can they be controlled?. Immunotherapy, 2015, 7, 843-846.	1.0	3
94	Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells. Blood, 2015, 126, 2219-2219.	0.6	2
95	Detection of self-reactive CD8 ⁺ T cells with an anergic phenotype in healthy individuals. Science, 2014, 346, 1536-1540.	6.0	162
96	Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation. Immunity, 2014, 41, 1040-1051.	6.6	450
97	Regulatory T cells in cancer immunotherapy. Current Opinion in Immunology, 2014, 27, 1-7.	2.4	612
98	Comprehensive exploration of autoantibody in BehÃ§et's disease: A novel autoantibody to claudin-1, an essential protein for tight junctions, is identified. Joint Bone Spine, 2014, 81, 546-548.	0.8	1
99	Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. Science, 2014, 346, 363-368.	6.0	86
100	Induction of CD8 Tâ€cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20â€mer NYâ€ESOâ€1f (NYâ€ESOâ€1 91â€110) peptide. International Journal of Cancer, 2013, 132, 345-354.	5.3	27
101	Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature, 2013, 500, 232-236.	13.7	2,339
102	Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17945-17950.	3.3	556
103	Antibody-based therapy in colorectal cancer. Immunotherapy, 2013, 5, 533-545.	1.0	31
104	Natural and Induced T Regulatory Cells in Cancer. Frontiers in Immunology, 2013, 4, 190.	2.2	202
105	Overcoming regulatory Tâ€cell suppression by a lyophilized preparation of Streptococcus pyogenes. European Journal of Immunology, 2013, 43, 989-1000.	1.6	8
106	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood, 2012, 119, 3097-3104.	0.6	65
107	Tax is a potential molecular target for immunotherapy of adult <scp>T</scp>â€cell leukemia/lymphoma. Cancer Science, 2012, 103, 1764-1773.	1.7	23
108	Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor Î±2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy, 2012, 14, 733-742.	0.3	56

#	Article	IF	Citations
109	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. Cancer Research, 2012, 72, 1672-1682.	0.4	46
110	Human bone marrow stromal cells simultaneously support <scp>B</scp> and <scp>T</scp>/<scp>NK</scp> lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. British Journal of Haematology, 2012, 157, 674-686.	1.2	12
111	Heteroclitic serological response in esophageal and prostate cancer patients after NYâ€ESOâ€1 protein vaccination. International Journal of Cancer, 2012, 130, 584-592.	2.3	38
112	UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. International Journal of Cancer, 2011, 129, 1126-1136.	2.3	19
113	NYâ€COâ€58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. International Journal of Cancer, 2010, 127, 381-393.	2.3	52
114	Regulatory T cells in tumor immunity. International Journal of Cancer, 2010, 127, 759-767.	2.3	749
115	Thioredoxin suppresses airway inflammation independently of systemic Th1/Th2 immune modulation. European Journal of Immunology, 2010, 40, 787-796.	1.6	37
116	Tumorâ€infiltrating ILâ€17â€producing Î³Î´ T cells support the progression of tumor by promoting angiogenesis. European Journal of Immunology, 2010, 40, 1927-1937.	1.6	200
117	NYâ€ESOâ€1 protein glycosylated by yeast induces enhanced immune responses. Yeast, 2010, 27, 919-931.	0.8	5
118	Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals. Clinical Cancer Research, 2010, 16, 2781-2791.	3.2	118
119	Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells. Journal of Immunology, 2010, 185, 3768-3776.	0.4	47
120	IFN-Î³-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis, 2009, 30, 1408-1415.	1.3	33
121	Glucocorticoidâ€induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigenâ€specific CD8⁺ T cells with tumor regression. Cancer Science, 2009, 100, 1317-1325.	1.7	34
122	Regulatory T Cellâ€“Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling. Cancer Research, 2008, 68, 5948-5954.	0.4	80
123	Induction of regulatory T cellâ€“resistant helper CD4+ T cells by bacterial vector. Blood, 2008, 111, 1404-1412.	0.6	28
124	NYâ€ESOâ€1: Review of an Immunogenic Tumor Antigen. Advances in Cancer Research, 2006, 95, 1-30.	1.9	311
125	De novo CD5-positive Diffuse Large B-cell Lymphoma of the Temporal Bone Presenting with an External Auditory Canal Tumor. Internal Medicine, 2006, 45, 733-737.	0.3	19
126	Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination. Journal of Immunology, 2006, 176, 6340-6346.	0.4	52

#	Article	IF	Citations
127	In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines. Journal of Clinical Investigation, 2006, 116, 1946-1954.	3.9	164
128	CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood, 2005, 106, 1008-1011.	0.6	160
129	Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18538-18543.	3.3	2,100
130	Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9253-9257.	3.3	102
131	IFN-Î³ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response. Journal of Immunology, 2005, 175, 4433-4440.	0.4	92
132	Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. Journal of Experimental Medicine, 2005, 201, 681-686.	4.2	118
133	Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes. American Journal of Hematology, 2004, 75, 179-189.	2.0	25
134	CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10902-10906.	3.3	152
135	The Soluble Notch Ligand, Jagged-1, Inhibits Proliferation of CD34+ Macrophage Progenitors. International Journal of Hematology, 2002, 75, 269-276.	0.7	40
136	Efficient ex vivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials. British Journal of Haematology, 2001, 114, 681-689.	1.2	22